Your session is about to expire
← Back to Search
Study Summary
This trial looks at how safe and tolerable a drug called apremilast is for kids (ages 6-17) with mild-moderate psoriasis.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2018 Phase 4 trial • 20 Patients • NCT03000309Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many participants have been enrolled in this experiment?
"To conduct this experiment, 50 eligible individuals are required. Potential subjects may join the study at either Dermatology Research Center of Oklahoma in Tulsa or Studies in Dermatology found in Cypress."
What potential side effects may be associated with Apremilast use?
"Our team at Power assigned Apremilast a score of 3 based on its Phase 3 status, which demonstrates the drug's efficacy and multiple safety confirmations."
Is the inclusion age for this research endeavor above eighty-five?
"This medical trial necessitates that participants are between the ages of 6 and 17, in accordance with its eligibility criteria."
Are there numerous locations within the United States where this experiment is being conducted?
"Currently, there are 9 different locations across the US where this study is being conducted. Tulsa, Cypress and Sugar Land are three of these sites; a full list can be found online to determine the closest centre for prospective participants."
Are any new patients being accepted into this experimental protocol?
"Indeed, the information on clinicaltrials.gov confirms that this trial is presently looking for participants and has been since October 24th 2023. The posting was most recently amended on November 10th 2023, with 50 people needed at 9 sites."
Who are the ideal candidates for enrolment in this experiment?
"A current clinical trial is searching for 50 young participants with plaque psoriasis, aged between 6 and 17. To be eligible, the candidate must meet a variety of criteria including: Psoriasis Area Severity Index score ranging from 2 to 15; Body surface area up to 15%; Weight over 20 kg; Age-and sex-specific BMI no lower than the fifth percentile on growth chart for children/adolescents; Ability to swallow study medication tablets; Diagnosis of chronic plaque psoriasis at least half a year before screening begins with Static Physician Global Assessment score evaluating as mild or moderate. Moreover, this medical trial requires that"
Share this study with friends
Copy Link
Messenger